BCL2L1 and colorectal carcinoma: Importantly, we reveal that this can be overcome by combining a BRAF inhibitor with a BCL-XL inhibitor, in both in vitro and in vivo models of BRAFV600E CRC, suggesting this combination regimen is worthy of clinical validation.